Secure CheckoutPersonal information is secured with SSL technology.
Free ShippingFree global shipping
No minimum order.
1. The spectrum of infectious diseases
1.2. 1. Hepatitis A;E
1.2. 2. Hepatitis C
1.2. 3. Hepatitis B, D
1.3. Herpes Zoster infections
1.4 HIV infections
1.4. TB and atypical mycobacterias
1.5. Bacterial infections
1.6 Non-mycobacterial opportunistic diseases
2. Comorbidities in patients with rheumatic disease
3. Drugs used in rheumatic disease
4. Risk/benefit management in the infectious phase.
5. Vaccine recommedations in patients with systemic rheumatic diseases
6. Education for patients/family and doctors
Infections in Systemic Autoimmune Diseases: Risk Factors and Management, Volume Sixteen describes the state-of-the-art of the risk factors and management treating the most common systemic autoimmune diseases (SADS). This updated volume consists of an introductory chapter that provides a brief overview of what different types of infectious diseases exist, followed by eight chapters detailing risk factors, guidelines and recommendations per different disease and bacterial infections. International in scope, the list of more than 20 contributors from Europa and America reads like a who’s who of clinical researchers in the field.
- Written by leading international clinical/surgical and scientific experts on Infection problems in systemic autoimmune diseases
- Provides a practical guide to the safer treatment of infections in patients with autoimmune diseases
- Includes a number of problems and recommendation that cannot be found in other books
- Designed as a ‘guide to clinical practice’ for management and risk interventions required by patients with SAD’s
Immunologists, rheumatologists, hematologists, cardiologists, postgraduate students and those working in autoimmune diseases, general medicine and hospital/pharmaceutical management
- No. of pages:
- © Elsevier 2020
- 16th March 2020
- Paperback ISBN:
Fabiola Atzeni received her degree in Medicine in 1995 from University of Cagliari and accreditation in Rheumatology in 2000. She received her Philosophy Doctorate in Experimental Immunology from University of Barcelona (2005). She is currently an Associate Professor and Senior Consultant at University of Messina. Before her current role, she was a Physician and Clinical Researcher at the Department of Rheumatology, Hospital L. Sacco, Milan. Her clinical and research interest lies in immunotherapies in autoimmune diseases with particular focus on the investigation and management of differential response to biological therapies in rheumatoid arthritis (RA) and Spondyloarthritis (SpA), cardiovascular aspects of the different rheumatic diseases with particular emphasis on arteriosclerosis and infectious aspects
Associate Professor and Senior Consultant, University of Messina, Italy
Massimo is Doctor of medicine at the University of Milan. And director of the department of infectious diseases
Department of Biomedical and Clinical Sciences "Luigi Sacco", University of Milan/UNIMI, Milan, Italy
Professor Juan Jose Gomez Reino MD is head of the rheumatology department at the University of Santiago. Juan obtained his MD and PhD from the Autonomous University of Madrid, he undertook his post doc training at the New York State University , Stony Brook USA. His clinical research mainly focuses on the search for improved treatments for Rheumatoid Arthrosis and Atherosclerosis which has resulted in many clinical treatment solutions.
Complejo Hospitalario Universitario de Santiago, Servicio de Reumatología, Travesia da Choupana, Santiago de Compostela, 15706, SPAIN
Dr Galloway is a clinical lecturer at King's College London and an honorary consultant in rheumatology at King's College Hospital. He runs the biologics assessment service for the rheumatology department. His research background has been in the study of biologic therapy safety. Within his role for KCL he works in the CRC accredited King's Clinical Trials Unit which has a large portfolio of investigator led trials. He also runs a phase 1 clinic in collaboration with the BRC facility and the Quintiles MHRA accredited Early Phase clinical trials unit at Guy's Hospital.
Kings College, London, UK